Overview

The Effects of DPPIs on Cognitive Function of Diabetic Patients

Status:
Not yet recruiting

Trial end date:
2024-07-15

Target enrollment:
0

Participant gender:
All

Summary

This is a single-center, randomized controlled clinical trial with a parallel-group design conducted at Minia University hospital.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Beni-Suef University

Collaborators:

Clinical Pharmacy Department, Faculty of Pharmacy, 6 October University
Faculty of Medicine, Minia University

Treatments:

Dipeptidyl-Peptidase IV Inhibitors
Metformin

Criteria

Inclusion Criteria:

Type-2 diabetic adult subjects (above 50 years old) who had uncontrolled (A1c=8-9 %) blood
glucose levels with an oral hypoglycemic drug at the screening visit were eligible to
participate.

Exclusion Criteria:

Those with type1 diabetes or ketoacidosis, end organ failure as chronic renal failure
(estimated serum creatinine level ≥ 1.5mg/dl in male and ≥ 1.4mg/dl in female), liver cell
failure (elevated alanine transaminase (ALT) and aspartate transaminase (AST) ≥ 2 folds),
and heart failure, previous history of pancreatitis, and pregnant or lactating females were
excluded from the study.